Nr546 weeks 1 4 Study guides, Class notes & Summaries

Midterm Exam: NR546/ NR 546 (NEW Update 2024/ 2025) Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Review |Weeks 1-4 | Questions and Verified Answers| 100% Correct- Chamberlain QUESTION Haloperidol, ziprasidone, and olanzapine Answer: increased risk of CVA, cognitive decline, and death in older adults with dementia and dementia related psychosis QUESTION aripiprazole black box warning Answer: medication with increased risk of suicide in...

Midterm Exam: NR546 / NR 546 (Latest Update 2024 / 2025) Advanced Pharmacology Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Guide | Weeks 1-4 Covered | Questions and Verified Answers | 100% Correct - Chamberlain Q: FGA side effects hyperprolactinemia, extrapyramidal symptom (EPS), QT pro- longation, tornadoes de pointes, blood dyscrasias, sedation, orthostatic hypoten- sion, dizziness. Q: Clozapine Answer: not indicated for use in acute presentation of schizophrenia, a...

Midterm Exam: NR546/ NR 546 (Latest Update 2024/ 2025) Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Guide |Weeks 1-4 Covered| Questions and Verified Answers| 100% Correct- Chamberlain Q: FGA side effects hyperprolactinemia, extrapyramidal symptom (EPS), QT pro- longation, tornadoes de pointes, blood dyscrasias, sedation, orthostatic hypoten- sion, dizziness. Q: Clozapine Answer: not indicated for use in acute presentation of schizophrenia, ab- solute n...

Final Exam: NR546 / NR 546 Advanced Pharmacology Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Final Exam Review | 2024 / 2025 Update | Complete Guide Questions and Verified Answers | Updated!! – Chamberlain Q: Adjunct treatment for depression Answer: Antipsychotic medications are sometimes prescribed at low doses as adjunctive medications for severe depression Q: Newer tx for resistant depression: esketamine (Spravato) Answer: nasal spray for the treatment of major d...

Nr546 Final Exam Study Guide-Nursing (NR546) 2023/2024 Chamberlain Collage. Nr546 Final exam study guide about:blank 1/17 Finale MDD-- Monoamine hypothesis of depression, prescribing considerations- the theory is that depression is caused by a deficiency in monoamine neurotransmission. And mania is the opposite - due to an excess of monoamine neurotransmission. This hasn't really been proven yet, so then the focus shifted to the monoamine receptor hypothesis - that the abnormality of re...

Nr546 Final Exam Study Guide-Nursing (NR546) 2023/2024 Chamberlain Collage. Nr546 Final exam study guide about:blank 1/17 Finale MDD-- Monoamine hypothesis of depression, prescribing considerations- the theory is that depression is caused by a deficiency in monoamine neurotransmission. And mania is the opposite - due to an excess of monoamine neurotransmission. This hasn't really been proven yet, so then the focus shifted to the monoamine receptor hypothesis - that the abnormality of re...

Nr546 Final Exam Study Guide - Nursing (NR546) 2023/2024 Chamberlain Collage. Nr546 Final exam study guide about:blank 1/17 Finale MDD-- Monoamine hypothesis of depression, prescribing considerations- the theory is that depression is caused by a deficiency in monoamine neurotransmission. And mania is the opposite - due to an excess of monoamine neurotransmission. This hasn't really been proven yet, so then the focus shifted to the monoamine receptor hypothesis - that the abnormality of ...

Final Exam: NR546/ NR 546 Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Final Exam Review | 2023/ 2024 Update| Complete Guide Questions and Verified Answers| Updated!! – Chamberlain Q: Adjunct treatment for depression Answer: Antipsychotic medications are sometimes prescribed at low doses as adjunctive medications for severe depression Q: Newer tx for resistant depression: esketamine (Spravato) Answer: nasal spray for the treatment of major depre...

NR546 / NR 546 ACTUAL MIDTERM EXAM 2022 QUESTIONS AND ANSWERS 1. Treatment with dopamine 2 receptor antagonists/partial agonists with antipsychotic pr the: A. Mesolimbic/mesostriatal pathway B. Mesocortical pathway C. Mesolimbic/mesostriatal and mesocortical pathways 2. A 44-year-old male with schizophrenia has been treated with a dopamine 2 receptor antagonist since initial diagnosis twelve years ago. He has recently begun experiencing difficulty with fluid movement of his arms as ...